Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease

Fabry disease is caused by deficient activity of α-galactosidase A (GLA) and characterized by systemic accumulation of glycosphingolipids, substrates of the enzyme. To gain insight into the pathogenesis of Fabry disease based on accumulated substrates, we examined the tissue and plasma distributions of globotriaosylceramide (Gb3) isoforms, and globotriaosylsphingosine (lyso-Gb3) and its analogues in a GLA knockout mouse, a model of Fabry disease, by means of liquid chromatography-mass spectrometry and nano-liquid chromatography-tandem mass spectrometry, respectively. The results revealed that the contents of these substrates in the liver, kidneys, heart, and plasma of GLA knockout mice were apparently higher than in those of wild-type ones, and organ specificity in the accumulation of Gb3 isoforms was found. Especially in the kidneys, accumulation of a large amount of Gb3 isoforms including hydroxylated residues was found. In the GLA knockout mice, the proportion of hydrophobic Gb3 isoforms was apparently higher than that in the wild-type mice. On the other hand, hydrophilic residues were abundant in plasma. Unlike that of Gb3, the concentration of lyso-Gb3 was high in the liver, and the lyso-Gb3/Gb3 ratio in plasma was significantly higher than those in the organs. The concentration of lyso-Gb3 was apparently higher than those of its analogues in the organs and plasma from both the GLA knockout and wild-type mice. This information will be useful for elucidating the basis of Fabry disease.

[1]  H. Sakuraba,et al.  Nano-LC-MS/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease , 2015, PloS one.

[2]  T. Meert,et al.  The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain , 2015, Neuroscience Letters.

[3]  R. Desnick,et al.  α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease. , 2015, The American journal of pathology.

[4]  Martin Strohalm,et al.  Fabry disease: renal sphingolipid distribution in the α-Gal A knockout mouse model by mass spectrometric and immunohistochemical imaging , 2015, Analytical and Bioanalytical Chemistry.

[5]  S. Suh,et al.  Globotriaosylceramide Induces Lysosomal Degradation of Endothelial KCa3.1 in Fabry Disease , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[6]  K. Satoh.  Globotriaosylceramide induces endothelial dysfunction in fabry disease. , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[7]  E. Fukusaki,et al.  Development of a lipid profiling system using reverse-phase liquid chromatography coupled to high-resolution mass spectrometry with rapid polarity switching and an automated lipid identification software. , 2013, Journal of chromatography. A.

[8]  G. A. van der Marel,et al.  Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry. , 2013, Clinical chemistry.

[9]  Mi Hee Lee,et al.  Possible role of transforming growth factor-β1 and vascular endothelial growth factor in Fabry disease nephropathy , 2012, International journal of molecular medicine.

[10]  J. Clarke,et al.  Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics. , 2012, Analytical chemistry.

[11]  M. Sánchez-Niño,et al.  Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  S. Suh,et al.  Globotriaosylceramide leads to K(Ca)3.1 channel dysfunction: a new insight into endothelial dysfunction in Fabry disease. , 2011, Cardiovascular research.

[13]  A. Zwinderman,et al.  Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. , 2011, Biochimica et biophysica acta.

[14]  R. Desnick,et al.  Substrate Reduction Augments the Efficacy of Enzyme Therapy in a Mouse Model of Fabry Disease , 2010, PloS one.

[15]  K. Ikeda,et al.  Highly sensitive localization analysis of gangliosides and sulfatides including structural isomers in mouse cerebellum sections by combination of laser microdissection and hydrophilic interaction liquid chromatography/electrospray ionization mass spectrometry with theoretically expanded multiple rea , 2010, Rapid communications in mass spectrometry : RCM.

[16]  A. Zwinderman,et al.  Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. , 2010, Biochimica et biophysica acta.

[17]  T. Kitagawa,et al.  Plasma globotriaosylsphingosine as a biomarker of Fabry disease. , 2010, Molecular genetics and metabolism.

[18]  R. Yoshida,et al.  Inner ear pathology of alpha-galactosidase A deficient mice, a model of Fabry disease. , 2010, Auris, nasus, larynx.

[19]  D. Lockhart,et al.  The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  T. Kanekura,et al.  Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease. , 2009, American journal of human genetics.

[21]  R. Brady,et al.  Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice , 2009, Neurobiology of Disease.

[22]  P. Luna,et al.  [Fabry disease]. , 2009, Anais brasileiros de dermatologia.

[23]  R. Brady,et al.  Elevated globotriaosylsphingosine is a hallmark of Fabry disease , 2008, Proceedings of the National Academy of Sciences.

[24]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[25]  R. Desnick.  α-Galactosidase A deficiency. Fabry disease , 2001 .

[26]  A. Kulkarni,et al.  Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Schiffmann,et al.  Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.